CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

INDICATION: Prostate cancer

Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to androgen receptor antagonist Xtandi enzalutamide and reduced cell invasion in an Xtandi-resistant human prostate cancer cell line. In xenograft mouse models of Xtandi-resistant prostate cancer, the CXCR2 inhibitor navarixin plus Xtandi reduced tumor growth more than either agent alone. The combination also decreased tumor growth in a xenograft mouse model of small-cell neuroendocrine prostate cancer, the most lethal subtype. Next steps include testing the combination of CXCR2 and androgen receptor inhibitors in patients with advanced prostate cancer...